Skip to main content

MedCloud Minute

Blog archive

GT Biopharma Expands AI Use in Next-Generation Cancer Drug Discovery

Key Takeaways

  • GT Biopharma expands AI-driven drug discovery to accelerate development of next-generation cancer immunotherapies.
  • AI optimizes tumor-targeting NK cell engagers and protein design to improve research efficiency and reduce costs.
  • AI-guided discovery supports TriKE platform development for blood cancer and solid tumor clinical programs.

GT Biopharma, a clinical-stage immuno-oncology company, is expanding its use of artificial intelligence to support the discovery and design of next-generation cancer therapies, applying AI to identify and optimize new tumor-targeting drug candidates. The implementation of AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins aims to accelerate development while reducing cost.

The AI-driven research platform analyzes biological and chemical data to help scientists prioritize promising therapeutic candidates before they enter laboratory testing. The approach is intended to improve the efficiency of early-stage drug discovery while reducing the time and cost associated with identifying potential cancer treatments.

According to the company, AI is being integrated with traditional laboratory research to guide decisions throughout the preclinical development process. The technology is expected to complement, rather than replace, experimental validation performed by researchers. The update arrives as GT Biopharma's clinical programs advance: GTB-3650 (Phase 1, CD33-expressing blood cancers) and GTB-5550 (Phase 1, B7-H3-expressing solid tumors), with the first GTB-5550 patient dosed in May 2026, all built on the company's TriKE platform.

Posted by MedCloudInsider Editors on 07/06/2026